Citigroup Inc Entrada Therapeutics, Inc. Transaction History
Citigroup Inc
- $190 Billion
- Q1 2025
A detailed history of Citigroup Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 18,586 shares of TRDA stock, worth $124,897. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,586
Previous 19,878
6.5%
Holding current value
$124,897
Previous $343,000
51.02%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$32.7 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$29.6 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$29.4 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$18.4 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$14.3 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $211M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...